bioAffinity Other Tuesday, November 17, 2026 +0.40 Positive

bioAffinity Reports Record Monthly Testing Volume in October

The company performed 235 CyPath Lung tests in October 2026, a 29% increase from October 2025 and approximately 45% of the total quarterly volume. This growth signals continued expansion in commercial reach and physician adoption of the noninvasive lung cancer diagnostic tool.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed